Literature DB >> 24363164

CD44 and CD24 cannot act as cancer stem cell markers in human lung adenocarcinoma cell line A549.

Raheleh Roudi1, Zahra Madjd, Marzieh Ebrahimi, Fazel Sahraneshin Samani, Ali Samadikuchaksaraei.   

Abstract

Cancer stem cells (CSCs) are subpopulations of tumor cells that are responsible for tumor initiation, maintenance and metastasis. Recent studies suggested that lung cancer arises from CSCs. In this study, the expression of potential CSC markers in cell line A549 was evaluated. We applied flow cytometry to assess the expression of putative stem cell markers, including aldehyde dehydrogenase 1 (ALDH1), CD24, CD44, CD133 and ABCG2. Cells were then sorted according to the expression of CD44 and CD24 markers by fluorescence-activated cell sorting (FACS) Aria II and characterized using their clonogenic and sphere-forming capacity. A549 cells expressed the CSC markers CD44 and CD24 at 68.16% and 54.46%, respectively. The expression of the putative CSC marker ALDH1 was 4.20%, whereas the expression of ABCG2 and CD133 was 0.93%. Double-positive CD44/133 populations were rare. CD44(+)/24(+) and CD44(+)/CD24(-/low) subpopulations respectively exhibited 64% and 27.92% expression. The colony-forming potentials in the CD44(+)/CD24(+) and CD44(+)/CD24(-/low) subpopulations were 84.37 ± 2.86% and 90 ± 3.06%, respectively, while the parental A549 cells yielded 56.65 ± 2.33% using the colony-formation assay. Both isolated subpopulations formed spheres in serum-free medium supplemented with basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF). CD44 and CD24 cannot be considered potential markers for isolating lung CSCs in cell line A549, but further investigation using in vivo assays is required.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24363164      PMCID: PMC6275711          DOI: 10.2478/s11658-013-0112-1

Source DB:  PubMed          Journal:  Cell Mol Biol Lett        ISSN: 1425-8153            Impact factor:   5.787


  42 in total

Review 1.  CD133.

Authors:  C Piechaczek
Journal:  J Biol Regul Homeost Agents       Date:  2001 Jan-Mar       Impact factor: 1.711

2.  Retinal oxidation activity and biological role of human cytosolic aldehyde dehydrogenase.

Authors:  A Yoshida; L C Hsu; V Davé
Journal:  Enzyme       Date:  1992

Review 3.  Pathology of lung cancer.

Authors:  William D Travis
Journal:  Clin Chest Med       Date:  2011-12       Impact factor: 2.878

4.  Eyes wide open: a critical review of sphere-formation as an assay for stem cells.

Authors:  Erika Pastrana; Violeta Silva-Vargas; Fiona Doetsch
Journal:  Cell Stem Cell       Date:  2011-05-06       Impact factor: 24.633

5.  Lung cancer stem cell: new insights on experimental models and preclinical data.

Authors:  Caroline Rivera; Sofia Rivera; Yohann Loriot; Marie-Catherine Vozenin; Eric Deutsch
Journal:  J Oncol       Date:  2010-12-16       Impact factor: 4.375

6.  Nomenclature of prominin-1 (CD133) splice variants - an update.

Authors:  C A Fargeas; W B Huttner; D Corbeil
Journal:  Tissue Antigens       Date:  2007-06

7.  Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells.

Authors:  Maria M Ho; Alvin V Ng; Stephen Lam; Jaclyn Y Hung
Journal:  Cancer Res       Date:  2007-05-15       Impact factor: 12.701

Review 8.  New molecularly targeted therapies for lung cancer.

Authors:  Sophie Sun; Joan H Schiller; Monica Spinola; John D Minna
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

9.  Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties.

Authors:  Elaine Lai-Han Leung; Ronald R Fiscus; James W Tung; Vicky Pui-Chi Tin; Lik Cheung Cheng; Alan Dart-Loon Sihoe; Louis M Fink; Yupo Ma; Maria Pik Wong
Journal:  PLoS One       Date:  2010-11-19       Impact factor: 3.240

10.  Identification and characterization of cells with cancer stem cell properties in human primary lung cancer cell lines.

Authors:  Ping Wang; Quanli Gao; Zhenhe Suo; Else Munthe; Steinar Solberg; Liwei Ma; Mengyu Wang; Nomdo Anton Christiaan Westerdaal; Gunnar Kvalheim; Gustav Gaudernack
Journal:  PLoS One       Date:  2013-03-04       Impact factor: 3.240

View more
  16 in total

Review 1.  Lung cancer and β-glucans: review of potential therapeutic applications.

Authors:  Raheleh Roudi; Shahla Roudbar Mohammadi; Maryam Roudbary; Monireh Mohsenzadegan
Journal:  Invest New Drugs       Date:  2017-03-16       Impact factor: 3.850

2.  Evidence for embryonic stem-like signature and epithelial-mesenchymal transition features in the spheroid cells derived from lung adenocarcinoma.

Authors:  Raheleh Roudi; Zahra Madjd; Marzieh Ebrahimi; Ali Najafi; Alireza Korourian; Ahmad Shariftabrizi; Ali Samadikuchaksaraei
Journal:  Tumour Biol       Date:  2016-04-05

3.  Sustainability of CD24 expression, cell proliferation and migration, cisplatin-resistance, and caspase-3 expression during mesenchymal-epithelial transition induced by the removal of TGF-β1 in A549 lung cancer cells.

Authors:  Seong-Kwan Kim; Jin-A Park; Dan Zhang; Sang-Hyun Cho; Hee Yi; Soo-Min Cho; Byung-Joon Chang; Jin-Suk Kim; Jae-Han Shim; A M Abd El-Aty; Ho-Chul Shin
Journal:  Oncol Lett       Date:  2017-06-16       Impact factor: 2.967

Review 4.  Lung cancer-associated brain metastasis: Molecular mechanisms and therapeutic options.

Authors:  Meysam Yousefi; Tayyeb Bahrami; Arash Salmaninejad; Rahim Nosrati; Parisa Ghaffari; Seyed H Ghaffari
Journal:  Cell Oncol (Dordr)       Date:  2017-09-18       Impact factor: 6.730

5.  Single-cell RNA-seq reveals the genesis and heterogeneity of tumor microenvironment in pancreatic undifferentiated carcinoma with osteoclast-like giant-cells.

Authors:  Xinbo Wang; Jiaying Miao; Sizhen Wang; Rongxi Shen; Shuo Zhang; Yurao Tian; Min Li; Daojun Zhu; Anlong Yao; Wei Bao; Qun Zhang; Xingming Tang; Xingyun Wang; Jieshou Li
Journal:  Mol Cancer       Date:  2022-06-22       Impact factor: 41.444

6.  DCLK1, a promising colorectal cancer stem cell marker, regulates tumor progression and invasion through miR-137 and miR-15a dependent manner.

Authors:  Sepideh Razi; Asieh Sadeghi; Zeynab Asadi-Lari; Kevin J Tam; Elham Kalantari; Zahra Madjd
Journal:  Clin Exp Med       Date:  2020-09-23       Impact factor: 3.984

Review 7.  Targeting Lung Cancer Stem Cells: Research and Clinical Impacts.

Authors:  Norashikin Zakaria; Nazilah Abdul Satar; Noor Hanis Abu Halim; Siti Hawa Ngalim; Narazah Mohd Yusoff; Juntang Lin; Badrul Hisham Yahaya
Journal:  Front Oncol       Date:  2017-05-05       Impact factor: 6.244

8.  NRP1-positive lung cancer cells possess tumor-initiating properties.

Authors:  Luis E Jimenez-Hernandez; Karla Vazquez-Santillan; Rosario Castro-Oropeza; Gustavo Martinez-Ruiz; Laura Muñoz-Galindo; Carolina Gonzalez-Torres; Carlo C Cortes-Gonzalez; Georgina Victoria-Acosta; Jorge Melendez-Zajgla; Vilma Maldonado
Journal:  Oncol Rep       Date:  2017-11-09       Impact factor: 3.906

Review 9.  Utilization of lung cancer cell lines for the study of lung cancer stem cells.

Authors:  Yuyi Wang; Ming Jiang; Chi Du; Yang Yu; Yanyang Liu; Mei Li; Feng Luo
Journal:  Oncol Lett       Date:  2018-03-14       Impact factor: 2.967

Review 10.  Is CD133 expression a prognostic biomarker of non-small-cell lung cancer? A systematic review and meta-analysis.

Authors:  Hong Wu; Xiao-wei Qi; Guang-ning Yan; Qing-bi Zhang; Chuan Xu; Xiu-wu Bian
Journal:  PLoS One       Date:  2014-06-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.